nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine in lactation
|
Pan, Xian |
|
|
52 |
2 |
|
artikel |
2 |
Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic–pharmacodynamic model
|
DeJongh, Joost |
|
|
52 |
2 |
|
artikel |
3 |
Imputation of missing clock times – application to procalcitonin concentration time course after birth
|
Bokor, Abigail J. |
|
|
52 |
2 |
|
artikel |
4 |
Information-theoretic evaluation of covariate distributions models
|
Hartung, Niklas |
|
|
52 |
2 |
|
artikel |
5 |
Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations
|
Behrens, Emily |
|
|
52 |
2 |
|
artikel |
6 |
Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?
|
van Valkengoed, Daan W. |
|
|
52 |
2 |
|
artikel |
7 |
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics
|
Liu, Feiyan |
|
|
52 |
2 |
|
artikel |
8 |
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models
|
Nyberg, Joakim |
|
|
52 |
2 |
|
artikel |